Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics

Xenon Pharmaceuticals Inc. (XENE): $30.87

0.95 (+3.18%)

POWR Rating

Component Grades













Add XENE to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where XENE ranks best; there it ranks ahead of 51.62% of US stocks.
  • XENE's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • XENE ranks lowest in Stability; there it ranks in the 11th percentile.

XENE Stock Summary

  • XENE's price/sales ratio is 85.98; that's higher than the P/S ratio of 97.4% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.05 for Xenon Pharmaceuticals Inc; that's greater than it is for only 6.31% of US stocks.
  • As for revenue growth, note that XENE's revenue has grown -42.68% over the past 12 months; that beats the revenue growth of only 3.83% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Xenon Pharmaceuticals Inc are NRIX, JNCE, SGMO, ATHX, and IMGN.
  • XENE's SEC filings can be seen here. And to visit Xenon Pharmaceuticals Inc's official web site, go to www.xenon-pharma.com.

XENE Valuation Summary

  • XENE's price/sales ratio is 39.7; this is 249.78% higher than that of the median Healthcare stock.
  • Over the past 83 months, XENE's EV/EBIT ratio has gone down 20.2.
  • XENE's price/sales ratio has moved up 34.4 over the prior 83 months.

Below are key valuation metrics over time for XENE.

Stock Date P/S P/B P/E EV/EBIT
XENE 2021-08-31 39.7 2.8 -12.6 -10.9
XENE 2021-08-30 38.0 2.7 -12.1 -10.3
XENE 2021-08-27 39.1 2.8 -12.4 -10.7
XENE 2021-08-26 38.2 2.7 -12.2 -10.4
XENE 2021-08-25 38.2 2.7 -12.2 -10.4
XENE 2021-08-24 38.2 2.7 -12.2 -10.4

XENE Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 7.93%.
  • Its year over year net income to common stockholders growth rate is now at 0.79%.
  • Its year over year revenue growth rate is now at 111.74%.
XENE's revenue has moved up $18,437,000 over the prior 34 months.

The table below shows XENE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 18.437 -69.502 -77.087
2021-09-30 19.85 -61.906 -63.985
2021-06-30 18.28 -58.053 -57.507
2021-03-31 29.446 -55.765 -36.089
2020-12-31 32.166 -48.124 -28.013
2020-09-30 30.345 -15.275 -26.991

XENE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XENE has a Quality Grade of D, ranking ahead of 7.55% of graded US stocks.
  • XENE's asset turnover comes in at 0.077 -- ranking 283rd of 681 Pharmaceutical Products stocks.
  • ADMP, ACUR, and ELTP are the stocks whose asset turnover ratios are most correlated with XENE.

The table below shows XENE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.077 1 -0.353
2021-03-31 0.132 1 -0.233
2020-12-31 0.154 1 -0.194
2020-09-30 0.153 1 -0.197
2020-06-30 0.157 1 -0.237
2020-03-31 0.094 1 -0.381

XENE Price Target

For more insight on analysts targets of XENE, see our XENE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.88 Average Broker Recommendation 1.17 (Strong Buy)

XENE Stock Price Chart Interactive Chart >

Price chart for XENE

XENE Price/Volume Stats

Current price $30.87 52-week high $36.42
Prev. close $29.92 52-week low $14.65
Day low $29.95 Volume 304,846
Day high $31.65 Avg. volume 458,024
50-day MA $30.78 Dividend yield N/A
200-day MA $27.39 Market Cap 1.64B

Xenon Pharmaceuticals Inc. (XENE) Company Bio

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.

XENE Latest News Stream

Event/Time News Detail
Loading, please wait...

XENE Latest Social Stream

Loading social stream, please wait...

View Full XENE Social Stream

Latest XENE News From Around the Web

Below are the latest news stories about Xenon Pharmaceuticals Inc that investors may wish to consider to help them evaluate XENE as an investment opportunity.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update

BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update after the close of U.S. financial markets on Tuesday, March 1, 2022. Conference Call/Webcast Information: Xenon will host a conference call and live audio webcast on Tuesday, March 1, 2022 at 4:30 pm Eastern Time (1:30 pm Pacific

Yahoo | February 22, 2022

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 16, 2022

Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. Fireside Chat Details: Date:Time:Presenter:Thursday, February 17, 20225:00-5:30 pm ETIan Mortimer, President and CEO The above listed dates and times are subject to change. Details on company pre

Yahoo | February 14, 2022

How Did Hedge Funds’ Xenon Pharmaceuticals Inc (XENE) Bets Fare?

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th, when the S&P 500 Index was trading around the […]

Yahoo | February 6, 2022

Xenon draws buyout speculation after Zogenix deal

Dealreporter flags Xenon Pharmaceuticals <> as a potential acquisition target following the agreement between Zogenix <> and UCB under which the Belgian drugmaker offered

Seeking Alpha | January 19, 2022

Read More 'XENE' Stories Here

XENE Price Returns

1-mo N/A
3-mo -6.82%
6-mo 5.43%
1-year 76.10%
3-year 223.58%
5-year 662.22%
YTD -1.18%
2021 103.12%
2020 17.32%
2019 107.77%
2018 123.36%
2017 -63.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.1563 seconds.